KUANGLI BIO-TECH HOLDINGS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.7 TWD | +0.79% |
|
+0.79% | -27.84% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 686.9 | 723.4 | 1,299 | 1,360 | 1,392 | 1,165 |
| Enterprise Value (EV) 1 | 321.8 | 377.7 | 1,144 | 1,253 | 1,578 | 1,373 |
| P/E ratio | -4.33 x | -38.3 x | -47.1 x | -21.6 x | 53.6 x | -16.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.45 x | 7.23 x | 3.05 x | 8.9 x | 3.89 x | 3.4 x |
| EV / Revenue | 3.02 x | 3.77 x | 2.69 x | 8.2 x | 4.41 x | 4.01 x |
| EV / EBITDA | -5.34 x | -8.42 x | -28.3 x | -20.6 x | 181 x | -23.6 x |
| EV / FCF | 42.6 x | -16.4 x | -13.9 x | 42 x | -7.68 x | 709 x |
| FCF Yield | 2.35% | -6.11% | -7.19% | 2.38% | -13% | 0.14% |
| Price to Book | 1.62 x | 1.81 x | 3.69 x | 4.33 x | 2.89 x | 2.08 x |
| Nbr of stocks (in thousands) | 45,643 | 45,643 | 45,643 | 45,643 | 51,171 | 57,239 |
| Reference price 2 | 15.05 | 15.85 | 28.45 | 29.80 | 27.20 | 20.35 |
| Announcement Date | 29/03/18 | 27/03/19 | 19/04/20 | 31/03/21 | 29/03/22 | 30/03/23 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 106.6 | 100.1 | 425.3 | 152.8 | 358.2 | 342.2 |
| EBITDA 1 | -60.27 | -44.88 | -40.45 | -60.97 | 8.717 | -58.24 |
| EBIT 1 | -110.4 | -45.48 | -43.6 | -64.35 | -10.09 | -89.03 |
| Operating Margin | -103.62% | -45.44% | -10.25% | -42.13% | -2.82% | -26.02% |
| Earnings before Tax (EBT) 1 | -158.9 | -17.69 | -24.56 | -59.51 | 60.74 | -84.78 |
| Net income 1 | -158.8 | -18.88 | -27.55 | -62.87 | 25.84 | -68.72 |
| Net margin | -149.04% | -18.86% | -6.48% | -41.16% | 7.21% | -20.09% |
| EPS 2 | -3.480 | -0.4136 | -0.6035 | -1.380 | 0.5071 | -1.226 |
| Free Cash Flow 1 | 7.547 | -23.07 | -82.22 | 29.82 | -205.6 | 1.937 |
| FCF margin | 7.08% | -23.05% | -19.33% | 19.52% | -57.39% | 0.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/03/18 | 27/03/19 | 19/04/20 | 31/03/21 | 29/03/22 | 30/03/23 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 186 | 208 |
| Net Cash position 1 | 365 | 346 | 154 | 107 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | 21.36 x | -3.569 x |
| Free Cash Flow 1 | 7.55 | -23.1 | -82.2 | 29.8 | -206 | 1.94 |
| ROE (net income / shareholders' equity) | -31.2% | -4.58% | -7.34% | -18.9% | 10.6% | -10% |
| ROA (Net income/ Total Assets) | -12.1% | -6.17% | -5.44% | -8.62% | -0.78% | -4.71% |
| Assets 1 | 1,313 | 306.1 | 506.5 | 729.5 | -3,332 | 1,460 |
| Book Value Per Share 2 | 9.310 | 8.730 | 7.710 | 6.880 | 9.420 | 9.770 |
| Cash Flow per Share 2 | 5.430 | 5.560 | 2.830 | 2.510 | 3.170 | 2.480 |
| Capex 1 | 2.8 | 0.16 | 2.64 | 8.23 | 40.4 | 34.2 |
| Capex / Sales | 2.63% | 0.16% | 0.62% | 5.39% | 11.27% | 10% |
| Announcement Date | 29/03/18 | 27/03/19 | 19/04/20 | 31/03/21 | 29/03/22 | 30/03/23 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -27.84% | 22.22M | |
| +19.53% | 20.69B | |
| 0.00% | 18.4B | |
| +12.46% | 11.56B | |
| -10.06% | 9.69B | |
| +16.41% | 7.66B | |
| +12.57% | 6.19B | |
| +3.02% | 4.62B | |
| -16.68% | 3.91B | |
| -6.70% | 3.69B |
- Stock Market
- Equities
- 6431 Stock
- Financials Kuangli Bio-Tech Holdings Co., Ltd.